Effects of PACAP in streptozotocin-induced rat model of diabetic retinopathy
Eszter
Bánki1*,
Krisztina
Szabadfi2,
Tamas
Atlasz3,
Katalin
Csanaky1,
Peter
Kiss1,
Dóra
Reglodi1,
Péter
Gönczi2,
Alíz
Szabó4,
Krisztina
Kovács4,
Laszlo
Mester4,
György
Sétáló5,
Ferenc
Jakab6 and
Róbert
Gábriel2
-
1
University of Pécs, Department of Anatomy, Hungary
-
2
University of Pécs, Department of Experimental Zoology and Neurobiology, Hungary
-
3
University of Pécs, Department of Sportbiology, Hungary
-
4
University of Pécs, Department of Biochemistry and Medical Chemistry, Hungary
-
5
University of Pécs, Department of Medical Biology, Hungary
-
6
University of Pécs, Department of Genetics and Molecular Biology, Hungary
Pituitary adenylate cyclase activating polypeptide (PACAP) has been shown to exert protective effects in models of neurodegenerative diseases, cerebral ischemia and retinal degeneration. Diabetic retinopathy is a leading cause of adult blindness. In the early stages the amacrine cells characteristically undergo degeneration. The aim of the present study was to investigate whether PACAP is effective in a model of diabetic retinopathy induced by 70mg/kg streptozotocin in Wistar rats. We administered intravitreal PACAP (100pmol) injection into the right eye, saline in the other, and retinas were evaluated with histologial, immuncytochemical (vertical sections and whole mount preparations) and molecular biological (Western blot, RT-PCR) methods. In streprozotocin-induced diabetic rats dopaminergic amacrine cells appeared to be degenerated, as revealed by thyrosine hydroxylase (TH) immunopositivity. Severe degeneration of dopaminergic amacrine cells was seen in the inner nuclear layer, shown by the shape of their soma and their connection. Morphometrical analysis showed significant reduction in the number of cells. Neuroprotective effects of PACAP were observed in streptozotocin-induced retinal degeneration. Intraocular PACAP treatment led to a nearly intact appearance of the soma, connections and cell number. According to RT-PCR and Western blot analyses using TH primary antibody, intensity of immunostaining was increased by PACAP treatment compared to diabetic retinas. In summary, intravitreal administration of PACAP protected dopaminergic amacrine cells, demonstrating its therapeutic potential in streptozotocin-induced diabetic retinopathy.
Supported by Richter Gedeon Ltd., GVOP-3.2.1-2004-04-0172/3.0, OTKA: K72592; F67830; CNK78480; T061766, PTE AOK 2009 Research Grant.
Conference:
IBRO International Workshop 2010, Pécs, Hungary, 21 Jan - 23 Jan, 2010.
Presentation Type:
Poster Presentation
Topic:
Disorders of the nervous system
Citation:
Bánki
E,
Szabadfi
K,
Atlasz
T,
Csanaky
K,
Kiss
P,
Reglodi
D,
Gönczi
P,
Szabó
A,
Kovács
K,
Mester
L,
Sétáló
G,
Jakab
F and
Gábriel
R
(2010). Effects of PACAP in streptozotocin-induced rat model of diabetic retinopathy.
Front. Neurosci.
Conference Abstract:
IBRO International Workshop 2010.
doi: 10.3389/conf.fnins.2010.10.00024
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
16 Apr 2010;
Published Online:
16 Apr 2010.
*
Correspondence:
Eszter Bánki, University of Pécs, Department of Anatomy, Pécs, Hungary, bankieszti@gmail.com